Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$196.79−10.01 (-4.84%)
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Moderna operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Moderna's operating income for the twelve months ending Jun 30, 2026 was -$3.32B. For fiscal 2025 it was -$3.07B. The highest annual figure on record is $13.30B in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.07B | – |
| FY2024 | Dec 31, 2024 | -$3.95B | – |
| FY2023 | Dec 31, 2023 | -$4.24B | -145.0% |
| FY2022 | Dec 31, 2022 | $9.42B | -29.2% |
| FY2021 | Dec 31, 2021 | $13.30B | – |
| FY2020 | Dec 31, 2020 | -$763.00M | – |
| FY2019 | Dec 31, 2019 | -$546.00M | – |
| FY2018 | Dec 31, 2018 | -$413.27M | – |
| FY2017 | Dec 31, 2017 | -$269.36M | – |
| FY2016 | Dec 31, 2016 | -$223.77M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$815.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.39B | – |
| Q4 FY2025 | Dec 31, 2025 | -$857.00M | – |
| Q3 FY2025 | Sep 30, 2025 | -$260.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$907.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.05B | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.25B | -20866.7% |
| Q3 FY2024 | Sep 30, 2024 | -$70.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.36B | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.27B | – |
| Q4 FY2023 | Dec 31, 2023 | $6.00M | -99.6% |
| Q3 FY2023 | Sep 30, 2023 | -$2.01B | -272.6% |
| Q2 FY2023 | Jun 30, 2023 | -$1.87B | -176.3% |
| Q1 FY2023 | Mar 31, 2023 | -$366.00M | -108.7% |
| Q4 FY2022 | Dec 31, 2022 | $1.58B | -70.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.17B | -67.2% |
| Q2 FY2022 | Jun 30, 2022 | $2.45B | -20.1% |
| Q1 FY2022 | Mar 31, 2022 | $4.23B | +233.9% |
| Q4 FY2021 | Dec 31, 2021 | $5.41B | – |
| Q3 FY2021 | Sep 30, 2021 | $3.56B | – |
| Q2 FY2021 | Jun 30, 2021 | $3.06B | – |
| Q1 FY2021 | Mar 31, 2021 | $1.27B | – |
| Q4 FY2020 | Dec 31, 2020 | -$275.00M | – |
| Q3 FY2020 | Sep 30, 2020 | -$235.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$122.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$131.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$130.56M | – |
| Q3 FY2019 | Sep 30, 2019 | -$130.76M | – |
| Q2 FY2019 | Jun 30, 2019 | -$143.71M | – |
| Q1 FY2019 | Mar 31, 2019 | -$141.64M | – |
| Q4 FY2018 | Dec 31, 2018 | -$153.03M | – |
| Q3 FY2018 | Sep 30, 2018 | -$85.82M | – |
| Q2 FY2018 | Jun 30, 2018 | -$97.02M | – |
| Q1 FY2018 | Mar 31, 2018 | -$77.40M | – |
| Q4 FY2017 | Dec 31, 2017 | -$41.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$67.87M | – |
| Q2 FY2017 | Jun 30, 2017 | -$94.19M | – |
| Q1 FY2017 | Mar 31, 2017 | -$65.46M | – |
See a number that looks wrong?